Predictors of Anticoagulation Control on Warfarin Therapy

Completed

• Conditions: Heart Valve Replacement; Atrial Fibrillation; Deep Vein Thrombosis

• Registration Number: NCT00905177
• Lead Sponsor: University of Pennsylvania

Brief Summary

The goal of this research study is to develop better dosing of anticoagulation medication in both Caucasian and African Americans through analysis of various genetic factors.

Detailed Description

This is a prospective cohort study among adult patients requiring warfarin therapy. Patients presenting for anticoagulation will be identified at the start of therapy and followed throughout their course until they reach maintenance dose. We will then develop a dosing equation for warfarin using patient, environmental and genetic factors.

Study Timeline

• Study First Submitted: 2009-05-18
• Study First Submitted QC: 2009-05-19
• Study First Posted: 2009-05-20
• Study Start: 2009-06
• Primary Completion: 2013-08
• Study Completion: 2013-08
• Status Verified: 2016-05
• Last Update Submitted: 2016-05-19
• Last Update Posted: 2016-05-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 687

Inclusion Criteria

• All Caucasians and African Americans who are new to warfarin therapy

Exclusion Criteria

• Under 21 years of age
• Non caucasian
• Non african american
• Have an abnormal INR before warfarin or heparin therapy
• Unable to provide consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (2)

Hospital of the University of Pennsylvania, Anticoagulation Management Center; 🇺🇸 Philadelphia, Pennsylvania, United States

Philadelphia Veteran Affairs Medical Center; 🇺🇸 Philadelphia, Pennsylvania, United States